To print this article, all you need is to be registered or login on Mondaq.com.
March 13, 2021 - On March 12, the FTC clarified
the extent of its temporary suspension of early termination of the
initial 30-day waiting period under the Hart-Scott-Rodino (HSR)
Act. Historically, the FTC and DOJ have exercised their discretion
to grant early termination of the initial waiting period in
appropriate circumstances if requested by the parties to an HSR
reportable transaction. On February 4, 2021, the DOJ and FTC
announced the temporary suspension of that policy during the
transition to the new administration and in light of a recent spike
MAJOR MARKET COMPARISON OF KEY COVID-19 LEGISLATION
As pharmaceutical companies worldwide race to supply vaccines
and therapeutics to fight the spread of COVID-19, understanding the
laws and regulations that could impact parties involved in the
COVID-19 pandemic supply chain is increasingly important. This
article provides an overview and comparison of legislation relevant
to manufacturers, suppliers, distributors, and health professionals
involved in the response to the COVID-19 pandemic in each of the
United States ( US ), European Union ( EU ),
United Kingdom ( UK ), and People s Republic of China
( PRC ), including measures to ensure (1) immunity from
COVID-19 countermeasure liability; (2) government ability to direct
(or redirect) resources; (3) emergency use authorizations; (4)
Powerhouse Points:
An effective antitrust compliance program should be
incorporated in a company s business practices and internal
controls.
Tone at the top is critical.
Senior management must be held accountable.
The importance of the antitrust compliance program should be
reflected in the company s employee evaluation, incentive, and
compensation systems.
Antitrust compliance training should be tailored to the
company s business.
An antitrust violation can be costly for a company. It can
subject the company to criminal fines. Executives may even be
sentenced to jail. If the company does business with a federal or
state agency, it may be subject to debarment, prohibiting the
To print this article, all you need is to be registered or login on Mondaq.com.
During his testimony before the Senate Judiciary Committee,
Judge Garland skillfully avoided taking firm positions on a variety
of topics-which made his statements regarding criminal justice
reform and the effect of systemic racism and implicit bias in the
justice system particularly notable. Criminal justice reform came
up several times, specifically in questions by Ranking Member
Grassley (R-IA) and Senators Chris Coons (D-DE), Pat Leahy (D-VT),
Cory Booker (D-NJ), Jon Ossoff (D-GA), Tom Cotton (R-AK), and John
Kennedy (R-LA). In each instance, Judge Garland was unequivocal
Imagine this: You litigate a case for years. Your opponent wins summary judgment. You appeal. The appellate court agrees that the summary judgment was erroneous and remands for trial.